OCT 02, 2020 8:00 AM PDT

Detecting Dystonia in the Blink of an AI

WRITTEN BY: Tara Fernandez

A team of scientists have created a diagnostic tool, powered by artificial intelligence (AI), that can pick up on the subtle signs of dystonia — a neurological condition that causes involuntary muscle contractions. Dystonia, an incurable condition, is notoriously difficult to diagnose and can affect parts of the body such as the jaw, eyelids, hands, and neck. These involuntary spasms can make daily tasks anywhere from challenging to impossible for patients, who often wait up to a decade to get a definitive diagnosis.

The AI experts used MRI scans taken from the heads of around 600 individuals, 392 of which had been diagnosed with dystonia. These were fed into the system, called DystoniaNet, which eventually “learned” to pick out differences between the healthy controls and those who had the condition. DystoniaNet was found to be able to diagnose dystonia with 98.8 percent accuracy in under a second.

Currently, diagnosing dystonia relies heavily on subjective clinical observations, of which as many as half of all cases remain misdiagnosed after an assessment. As a result, patients continue to live with their painful, prolonged muscle contractions that result in abnormal postures and movements.

Kristina Simonyan, senior author of the study said, “There is a critical need to develop, validate and incorporate objective testing tools for the diagnosis of this neurological condition, and our results show that DystoniaNet may fill this gap.”

DystoniaNet joins a suite of other deep learning AI algorithms for clinical diagnostics currently in development which are able to “see” changes in MRI scans that are invisible to the naked eye. The platform can analyze 3 dimensional brain scans at a pixel level, detecting patterns that would escape even seasoned physicians. Future work aims to expand the DystoniaNet platform to be able to detect even more types of dystonia. Trials at multiple clinical sites are also being set up to validate the system with larger cohorts of patients.


Source: Massachusetts Eye and Ear.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 03, 2020
Cancer
Improving Diagnostics in Breast Cancer
AUG 03, 2020
Improving Diagnostics in Breast Cancer
Diagnostics is one of the essential tools in a physician’s toolkit. A good diagnostic test can identify whether a ...
SEP 28, 2020
Cancer
A New Transcriptomics Program in the Works Glioma Diagnosis
SEP 28, 2020
A New Transcriptomics Program in the Works Glioma Diagnosis
The future of medicine is “personalized healthcare.” However, testing remains a critical hurdle researcher&r ...
OCT 08, 2020
Cardiology
Omega-3 Enriched Chicken as a Fish Alternative for Omega-3 Fatty Acids
OCT 08, 2020
Omega-3 Enriched Chicken as a Fish Alternative for Omega-3 Fatty Acids
We have all seen those articles telling us to get more omega-3 fatty acids in our diet. Many studies point to these spec ...
OCT 23, 2020
Clinical & Molecular DX
Follow Your Heart: A Genetic Predictor of Cardiovascular Disease
OCT 23, 2020
Follow Your Heart: A Genetic Predictor of Cardiovascular Disease
Cardiovascular disease is the leading cause of death globally, resulting in the loss of nearly 18 million lives each yea ...
NOV 12, 2020
Clinical & Molecular DX
Study Shows 1 in 5 COVID Tests Are False Positives
NOV 12, 2020
Study Shows 1 in 5 COVID Tests Are False Positives
  A study published in The BMJ has brought to light that the rapid finger-prick COVID-19 test may not be quite as r ...
NOV 18, 2020
Clinical & Molecular DX
Nerve Damage as a Prognostic Marker for Rare Autoimmune Disease
NOV 18, 2020
Nerve Damage as a Prognostic Marker for Rare Autoimmune Disease
Researchers have identified a new prognostic biomarker for Guillain-Barré syndrome (GBS), a rare autoimmune disor ...
Loading Comments...